Spero Therapeutics (SPRO) Receives FDA Fast Track Designation for SPR994 for treatment of cUTI and Acute Pyelonephritis - StreetInsider.com

Spero Therapeutics (SPRO) Receives FDA Fast Track Designation for SPR994 for treatment of cUTI and Acute Pyelonephritis  StreetInsider.com

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Spero Therapeutics, Inc. (Nasdaq: SPRO), ...



Comments

Popular posts from this blog

Summary of Society for Maternal-Fetal Medicine (SMFM) Consult Series #52: Diagnosis and management of fetal growth restriction - Contemporary Obgyn

BTS Clinical Statement on air travel for passengers with respiratory disease - Thorax (BMJ)